Please login to the form below

Not currently logged in
Email:
Password:

#ChatAFib

This page shows the latest #ChatAFib news and features for those working in and with pharma, biotech and healthcare.

Social media – part of the routine

Social media – part of the routine

ChatAFib, in line with the 2013 European Stroke Congress. It generated an estimated 720, 900 impressions and 305 tweets from 76 participants and gained widespread recognition in the pharma industry as

Latest news

  • Boehringer continues award-winning ChatAFib tweet chat Boehringer continues award-winning ChatAFib tweet chat

    Boehringer Ingelheim will today host the third installment in its award-winning #ChatAFib tweet chat programme. . ... ChatAFib reached over 3 million timelines, received strong feedback from attendees and observers, and drove engagement on the topic of

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Are we #winning? Are we #winning?

    Boehringer Ingelheim is a notable social media trailblazer, being one of the first to join Twitter and to successfully execute award-winning TweetChats (#ChatAfib, #COPDchat), engaging experts, patients and media.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics